Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Shares Issued (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Shares Issued for 6 consecutive years, with -$378000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 154.23% year-over-year to -$378000.0, compared with a TTM value of $325000.0 through Dec 2025, down 80.93%, and an annual FY2025 reading of $325000.0, down 80.93% over the prior year.
  • Shares Issued was -$378000.0 for Q4 2025 at Cytek Biosciences, down from $664000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $215.4 million in Q3 2021 and bottomed at -$378000.0 in Q4 2025.
  • Average Shares Issued over 5 years is $12.3 million, with a median of $278500.0 recorded in 2023.
  • The sharpest move saw Shares Issued soared 226607.37% in 2021, then crashed 154.23% in 2025.
  • Year by year, Shares Issued stood at $215.4 million in 2021, then tumbled by 99.92% to $168000.0 in 2022, then skyrocketed by 429.17% to $889000.0 in 2023, then fell by 21.6% to $697000.0 in 2024, then plummeted by 154.23% to -$378000.0 in 2025.
  • Business Quant data shows Shares Issued for CTKB at -$378000.0 in Q4 2025, $664000.0 in Q2 2025, and $39000.0 in Q1 2025.